CJC-1295 Ipamorelin: Research on a Growth Hormone Peptide Stack
CJC-1295 Ipamorelin: Research on a Growth Hormone Peptide Stack
CJC-1295 ipamorelin is the most-studied combination in the GHRH analog research literature. The CJC-1295 ipamorelin stack targets two distinct but complementary receptor systems: GHRH-R (the growth hormone-releasing hormone receptor, activated by CJC-1295) and GHSR (the growth hormone secretagogue receptor, activated by ipamorelin). When both receptors are simultaneously engaged, the resulting intracellular signaling is greater than either compound alone.
The mechanistic rationale comes from Cunha and Mayo (2002), who demonstrated that co-activation of GHRH-R and GHSR in transfected cell lines produced a cAMP response approximately twice that of GHRH-R activation alone [8]. The synergy is not mediated by the canonical PLC/PKC pathway downstream of GHSR; instead, a direct receptor-receptor interaction is proposed. This in vitro finding is the molecular basis for the stack's research interest.
What Is the CJC-1295 Ipamorelin Stack Studied For?
In preclinical and early clinical research, the CJC-1295 plus ipamorelin combination is studied for synergistic amplification of GH pulse amplitude. CJC-1295 elevates the baseline GH secretory floor via continuous GHRH-R stimulation; ipamorelin (a GHSR agonist) triggers an acute GH pulse through a mechanistically distinct pathway [7][8]. The combination is studied for lean body mass and fat metabolism outcomes in preclinical models.
Ipamorelin itself is the most selective GH secretagogue identified in early research: it stimulates GH release in conscious swine with potency and efficacy comparable to GHRP-6 but without releasing ACTH, cortisol, FSH, LH, prolactin, or TSH at doses more than 200-fold above the GH-effective dose [7]. This selectivity is the pharmacological property that makes ipamorelin the preferred pairing in combination research.
CJC-1295 Ipamorelin: Preclinical Evidence on Body Composition
Rodent studies with GHRH analogs and GHSR agonists separately report reductions in adipose tissue and preservation of lean body mass under GH-axis stimulation. Ipamorelin produced dose-dependent increases in longitudinal bone growth (from 42 to 44–52 micrometers per day) in adult female rats over 15 days [9], with pronounced and dose-dependent body weight gain. In a separate study, ipamorelin counteracted glucocorticoid-induced bone loss and produced a 4-fold increase in periosteal bone formation rate, alongside increased muscle strength measured as maximum tetanic tension [10].
CJC-1295 in GHRH knockout mice restored normal body weight, body length, and body composition (lean and fat mass) with once-daily dosing [5]. Less frequent dosing produced only partial normalization.
No randomized controlled trial in humans has examined the CJC-1295/ipamorelin combination specifically for weight loss or muscle building as primary endpoints. The preclinical evidence is from separate compound studies, and extrapolation to combined human use is not supported by the published literature.
Reported Side Effects of the CJC-1295 Ipamorelin Combination
Combined use adverse events reported in clinical and observational data include injection-site erythema, flushing, transient headache, increased hunger, joint discomfort, and water retention. Ipamorelin monotherapy in swine demonstrated no significant ACTH or cortisol release — the principal safety concern with older GH secretagogues [7]. CJC-1295 in the Teichman 2006 trial was well tolerated at 30–60 mcg/kg with vasodilatory reactions at higher doses [1].
For CJC-1295 side effects documented in studies, see the dedicated safety page. The cardiovascular and immunogenicity concerns raised in the FDA's 2024 PCAC review apply to CJC-1295 specifically and are covered there.
CJC-1295 Ipamorelin vs MK-677: Comparing Growth Hormone Secretagogues
MK-677 (ibutamoren) is a nonpeptide oral GHSR agonist with a half-life of approximately 4.7 hours. In a 7-day human trial, 5 or 25 mg once-daily oral MK-677 increased GH pulse frequency and IGF-1 levels in healthy young men without significantly altering 24-hour cortisol levels [16]. The oral route and longer half-life distinguish MK-677 from the injectable CJC-1295/ipamorelin combination.
CJC-1295/ipamorelin and MK-677 target related but distinct receptor systems: CJC-1295 activates GHRH-R while both ipamorelin and MK-677 activate GHSR, but ipamorelin is a peptide administered subcutaneously with a different half-life profile than the oral small-molecule MK-677. No direct comparative trial between CJC-1295/ipamorelin and MK-677 has been published. The two approaches differ in route, half-life, regulatory status, and available clinical evidence.